Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.3%. By the end of trading, Questcor Pharmaceuticals fell $2.27 (-8.1%) to $25.90 on light volume. Throughout the day, 4.4 million shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 5.9 million shares. The stock ranged in price between $25.69-$27.70 after having opened the day at $27.70 as compared to the previous trading day's close of $28.17. Other companies within the Health Care sector that declined today were:
), down 23%,
), down 18.7%,
), down 14.2%, and
), down 9.2%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $1.61 billion and is part of the drugs industry. The company has a P/E ratio of 10.6, below the S&P 500 P/E ratio of 17.7. Shares are down 33.9% year to date as of the close of trading on Thursday. Currently there are five analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and two rate it a hold.
TheStreet Ratings rates Questcor Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.
- You can view the full Questcor Ratings Report.
On the positive front,
), up 29.3%,
), up 26.7%,
), up 16.7%, and
), up 13.8%, were all gainers within the health care sector with
) being today's featured health care sector leader.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider
) while those bearish on the health care sector could consider
- Find other investment ideas from our top rated ETFs lists.
Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade